Hey folks,Everybody's MBA's not withstanding, just a word from the clinical arena. I do not own Fox Hollow, but am intimately familiar with the Silverhawk since I work in Vascular sales. There are several issues with Silverhawk that I will list. First and foremost, long term patency is poor with this product. A recent study cited 80% patency out to 6 months, but a dismal 20% after 6 months. This means treated vessels are not staying open and require additional therapy. The second issue is cost. Hospital administrators hate this product precisely because it is expensive and does not deliver. At this time there is no cure for intimal hyperplasia or PAD, until that occurs I believe this stock is going to be a disappointment .
Hey dtrapp,Thank you for these insights. I have been looking at this stock for awhile, but have not bought. Morningstar is cautiously bullish, so it has merited a long look from me. But your words make me want to keep watching and not buy. Perhaps the upcoming NightHawk will prove to be more efficacious than SilverHawk.Any further info from your experience would be great as things move along.-- Jamie
well, I did end up buying. and now that the company has been bought out I'm up about 14% since my purchase. I think that ev3's offer undervalues the company, but I believe there is little chance of defeating it, and ev3 is a stock with some potential. I'm not sure if I'm holding, though, we'll see.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |